Pacemaker, Ablation Atrial Fibrillation Studies Evaluated By FDA Panel

Quality of life endpoints are sufficient for approving implantable pacemakers and defibrillators as treatments for atrial fibrillation, even without assurances that the devices provide long-term clinical benefit, FDA's Circulatory Systems Device Panel concluded April 6 in Gaithersburg, Maryland.